News for Healthier Living

Breakthrough Gene Therapy Shows Hope for Treating Fatal Childhood Leukodystrophy

Myrtelle Inc. ("Myrtelle"), a pioneering clinical-stage gene therapy company developing transformative treatments for neurodegenerative diseases, today announced the publication of interim results in Nature Medicine from a pioneering clinical study , reporting by researchers the first-in-human application of a gene therapy designed to restore myelin in the brains of children affected by Canavan Disease (CD), a rare and fatal pediatric leukodystrophy. The investigational treatment, known as MYR-101, uses a novel viral vector (rAAV-Olig001) with unique tropism for oligodendrocytes, the brain's myelin- producing cells.

September 16, 2025


September 18 2025

September 17 2025

September 16 2025

September 15 2025

September 14 2025

September 13 2025

September 12 2025

September 11 2025

September 10 2025

September 9 2025

September 8 2025

September 7 2025

September 6 2025

September 5 2025

September 4 2025